Research programme: melanocortin-4 receptor antagonists - Gene LogicAlternative Names: Melanocortin-4 receptor antagonists research programme - Gene Logic
Latest Information Update: 27 Jul 2004
At a glance
- Originator Gene Logic
- Mechanism of Action Melanocortin type 4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cachexia
Most Recent Events
- 27 Jul 2004 Gene Logic has acquired the MC4 antagonist research programme from Millennium Pharmaceuticals
- 04 Jun 2004 Discontinued - Preclinical for Cachexia in USA (unspecified route)
- 23 Jul 1999 Preclinical development for Cachexia in USA (Unknown route)